Not Signed In - GlaxoSmithKline Initiates Head-to-Head Study Of Cervical Cancer Vaccines
Fri, 19 Jan 2007 08:00 AM EST
... GlaxoSmithKline (NYSE: GSK) announced today the initiation of the first study of its kind designed to compare the immunogenicity of its cervical cancer candidate vaccine, CERVARIX(R), versus Gardasil(R). The primary objective of the head-to-head trial is to compare the immune responses to HPV types 16 and 18 in U.S. women 18 to 26-years-old. [click link for full article] ...
Related Topics
- Head Injury
- Head Lice
- Cervical Cancer
- Vaccines & Immunizations
- Head and Neck Cancer
- Echinacea
- Neck Disorders and Injuries
- Neck/Head Cancer
- Cervical Dysplasia
- Cancers
- Uterine Cancer
- Permanent muscle weakness in the face or head
- Decreased sensation in parts of the face or head
- Thyroid Cancer
- Head and Brain Injuries
- Cervical Stenosis
- Tremor
- Lymphedema
- Cancer
- Cancer Radiation Therapy
email this page
print this page
bookmark this page
feedback on this page
